Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

BioVie Achieved Alignment With The FDA On Its Upcoming SUNRISE-PD Trial In Parkinson's Disease. As A Result, The Company Is Conducting Trial Start-up Activities With A View To Initiate Patient Screening In Q4 2024

Author: Benzinga Newsdesk | August 08, 2024 06:09am

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopa.
Company engaged in trial start-up activities and plans to initiate patient screening Q4 2024

Posted In: BIVI